CN101060858A - 确定口服灭活疫苗剂量的方法 - Google Patents

确定口服灭活疫苗剂量的方法 Download PDF

Info

Publication number
CN101060858A
CN101060858A CNA2005800345580A CN200580034558A CN101060858A CN 101060858 A CN101060858 A CN 101060858A CN A2005800345580 A CNA2005800345580 A CN A2005800345580A CN 200580034558 A CN200580034558 A CN 200580034558A CN 101060858 A CN101060858 A CN 101060858A
Authority
CN
China
Prior art keywords
vaccine
species
level
activation
individuals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800345580A
Other languages
English (en)
Chinese (zh)
Inventor
R·克兰西
P·科曼斯
G·派恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hunter Immunology Pty Ltd
Original Assignee
Hunter Immunology Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2004904671A external-priority patent/AU2004904671A0/en
Application filed by Hunter Immunology Pty Ltd filed Critical Hunter Immunology Pty Ltd
Publication of CN101060858A publication Critical patent/CN101060858A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CNA2005800345580A 2004-08-17 2005-08-17 确定口服灭活疫苗剂量的方法 Pending CN101060858A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2004904671A AU2004904671A0 (en) 2004-08-17 Method for determining dosage for an oral killed vaccine
AU2004904671 2004-08-17

Publications (1)

Publication Number Publication Date
CN101060858A true CN101060858A (zh) 2007-10-24

Family

ID=35907168

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800345580A Pending CN101060858A (zh) 2004-08-17 2005-08-17 确定口服灭活疫苗剂量的方法

Country Status (6)

Country Link
US (1) US20070269376A1 (https=)
EP (1) EP1793848A4 (https=)
JP (1) JP2008509936A (https=)
CN (1) CN101060858A (https=)
CA (1) CA2578189A1 (https=)
WO (1) WO2006017894A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008109958A1 (en) * 2007-03-15 2008-09-18 Hunter Immunology Limited Methods for evaluation of oral vaccines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778750A (en) * 1986-02-19 1988-10-18 Imreg, Inc. Diagnostic methods for immune function
AUPQ761200A0 (en) * 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
US7914799B2 (en) * 2001-08-27 2011-03-29 Immunitor USA, Inc. Anti-fungal composition
US8758759B2 (en) * 2002-10-17 2014-06-24 Enzo Biochem, Inc. Transmucosal administration of aggregated antigens

Also Published As

Publication number Publication date
CA2578189A1 (en) 2006-02-23
WO2006017894A1 (en) 2006-02-23
JP2008509936A (ja) 2008-04-03
US20070269376A1 (en) 2007-11-22
EP1793848A1 (en) 2007-06-13
EP1793848A4 (en) 2008-06-11

Similar Documents

Publication Publication Date Title
EP1009413B1 (en) Use of immunostimulatory oligonucleotides for preventing or treating asthma
Kang et al. Pluronic® F127 enhances the effect as an adjuvant of chitosan microspheres in the intranasal delivery of Bordetella bronchiseptica antigens containing dermonecrotoxin
US10857228B2 (en) Adjuvant for vaccines, vaccine, and immunity induction method
Murphy et al. Lung defenses against infection: a clinical correlation
JP2016047048A (ja) 経口不活化ワクチン及びそれを提供するための方法
EP1689433B1 (en) Compositions and methods for activating innate and allergic immunity
JP2009541281A (ja) キチンマイクロ粒子を含む組成物およびそれらの医学的使用
CN101060858A (zh) 确定口服灭活疫苗剂量的方法
CN110573179B (zh) 包含弱毒化的肺炎链球菌菌株的药剂学组合物及其用途
WO2008133645A2 (en) Combination vaccine for prevention of tularemia
AU2005274679A1 (en) Method for determining dosage for an oral killed vaccine
TW201105365A (en) Vaccine for mycoplasma infection
AU2008226340B2 (en) Treatment or prophylaxis of asthma
Vintiñi et al. Nasal administration of a non-viable Lactobacillus casei to infant mice modulates lung damage induced by Poly I: C and hyperreactivity in airways
EP1181051A1 (en) METHODS AND COMPOUNDS FOR THE TREATMENT OF IMMUNOLOGICALLY-MEDIATED DISEASES USING i MYCOBACTERIUM VACCAE /i
AU2005274680B2 (en) Oral killed vaccines and method for providing same
CN110141660A (zh) 鼠疫菌f1疫苗液体气溶胶肺递送免疫小鼠模型
Wallace et al. Protection against non‐typable Haemophilus influenzae following sensitization of gut associated lymphoid tissue: Role of specific antibody and phagocytes
Wright et al. rhIL-12 as adjuvant augments lung cell cytokine responses to pneumococcal whole cell antigen
Yakabe et al. Understanding Host Immunity and the Gut Microbiota Inspires the New Development of Vaccines and Adjuvants. Pharmaceutics 2021, 13, 163
WO2026068728A1 (en) A klebsiella pneumoniae vaccine
WO2010032139A1 (en) Bacterial and fungal vaccines for the treatment of asthma
Crook et al. Haemophilus spp.
Horner et al. Mucosal adjuvanticity of immunostimulatory
HK1029515B (en) Use of immunostimulatory oligonucleotides for preventing or treating asthma

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20071024